
Dr. Ravi Thadhani will oversee the academic and clinical enterprises at Cedars-Sinai. (photo by Cedars-Sinai)
Cedars-Sinai has appointed Dr. Ravi Thadhani as its inaugural executive vice president, chief physician executive and dean of the medical faculty, creating a new leadership position that brings the organization’s clinical, research and educational missions under a single executive.
Thadhani will assume the role on Sept. 1, overseeing Cedars-Sinai’s academic and clinical enterprises while leading department chairs, institute directors, executive vice deans, vice deans and chief medical officers. The appointment establishes a unified leadership structure designed to coordinate patient care, medical education and scientific research across the health system.
Thadhani succeeds Dr. Shlomo Melmed, who served as dean of the medical faculty and executive vice president of Medicine and Health Sciences for 28 years. Melmed will become dean emeritus of the Medical Faculty and executive advisor to Slavin.
“Dr. Thadhani is the ideal leader to succeed Dr. Melmed,” Cedars-Sinai President and CEO Dr. Peter L. Slavin said. “His extensive background in organizational leadership, commitment to clinical medicine and academic excellence and robust scientific record position him to advance every dimension of our enterprise.”
Thadhani most recently served as executive vice president of Clinical Affairs and chief medical officer for Cedars-Sinai Medical Center and Cedars-Sinai Health System. In his expanded role, he will continue overseeing clinical quality, patient safety, medical affairs and standards of care while assuming responsibility for Cedars-Sinai Health Sciences University and the Burns and Allen Research Institute.
A physician-scientist specializing in nephrology, Thadhani has held leadership positions at several of the nation’s leading academic medical institutions. He began his career at Massachusetts General Hospital and Harvard Medical School before joining Cedars-Sinai as vice dean for Research and Education from 2017 to 2019. He later returned to Harvard Medical School, serving as professor of medicine, chief academic officer and dean for Faculty Affairs at Mass General Brigham.
In 2022, Thadhani was appointed executive vice president for health affairs at Emory University, where he also served as vice chair of the Emory Healthcare Board of Directors and executive director of the Woodruff Health Sciences Center, overseeing Emory’s schools of medicine, nursing and public health.
Throughout his career, Thadhani has authored or co-authored more than 300 scientific papers published in leading peer-reviewed medical journals, including The New England Journal of Medicine, The Lancet and the Journal of the American Medical Association.
His research has focused on kidney disease and preeclampsia, a pregnancy complication that is a leading cause of maternal and infant illness and death. Working with collaborators at Cedars-Sinai, Thadhani helped develop the first U.S. Food and Drug Administration-approved test to predict the condition.
“I am deeply honored to step into this role at such a pivotal moment for Cedars-Sinai,” Thadhani said. “I am grateful to Dr. Melmed for the extraordinary foundation he has built, and I look forward to working closely with our talented leaders and faculty to forge the next chapter of our academic and clinical mission.”
For information, visit cedars-sinai.org.



0 Comment